当前位置: X-MOL 学术Ther. Adv. Med. Oncol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Patterns of treatment and outcome with 500-mg fulvestrant in postmenopausal women with hormone receptor-positive/HER2-negative metastatic breast cancer: a real-life multicenter Italian experience
Therapeutic Advances in Medical Oncology ( IF 4.3 ) Pub Date : 2019-06-04 , DOI: 10.1177/1758835919833864
Raffaella Palumbo 1 , Federico Sottotetti 2 , Erica Quaquarini 3 , Anna Gambaro 4 , Antonella Ferzi 5 , Barbara Tagliaferri 1 , Cristina Teragni 1 , Luca Licata 1 , Francesco Serra 1 , Pietro Lapidari 1 , Antonio Bernardo 1
Affiliation  

Breast cancer, one of the three most common malignancies worldwide, is a disease strongly related with age, with the highest incidence among elderly, postmenopausal women.1 Approximately 70–80% of breast cancers are estrogen receptor (ER) or progesterone receptor (PgR)-positive and thus potentially sensitive to endocrine therapy (ET). The main international guidelines endorse ET as the preferred first-line option for hormone receptor-positive (HR+) disease in postmenopausal women, even in the presence of visceral disease (but not in cases of visceral crisis or concern/proof of endocrine resistance). At some point of her clinical history, every woman with HR+/HER2 metastatic breast cancer (MBC) will receive one or more ET lines in the context of a sequential strategy.2 The choice of the upfront and subsequent agents mainly depends on the type of adjuvant ET as well as the disease-free interval from its completion; these can be aromatase inhibitors (AIs), tamoxifen, or fulvestrant.3 However, almost all women with initially endocrine-sensitive disease will develop a resistance to ET, either as an early failure (de novo resistance), or as a progression after an initial response (acquired resistance).4 The optimal sequence of single endocrine agents and combinations with targeted agents is yet to be defined and is a research priority.

中文翻译:

500 毫克氟维司群治疗激素受体阳性/HER2 阴性转移性乳腺癌绝经后妇女的模式和结果:真实的多中心意大利经验

乳腺癌是世界上最常见的三种恶性肿瘤之一,是一种与年龄密切相关的疾病,在老年、绝经后妇女中发病率最高。1大约 70-80% 的乳腺癌是雌激素受体 (ER) 或孕激素受体 (PgR) 阳性,因此可能对内分泌治疗 (ET) 敏感。主要的国际指南认可 ET 作为绝经后妇女激素受体阳性 (HR+) 疾病的首选一线选择,即使存在内脏疾病(但在内脏危机或担心/证明内分泌抵抗的情况下)。在她临床病史的某个时间点,每位患有 HR+/HER2 转移性乳腺癌 (MBC) 的女性都将在序贯策略的背景下接受一个或多个 ET 线。2前期和后续药物的选择主要取决于辅助 ET 的类型以及完成后的无病间隔时间;这些可以是芳香酶抑制剂 (AI)、他莫昔芬或氟维司群。3然而,几乎所有最初患有内分泌敏感疾病的女性都会对 ET 产生耐药性,或者作为早期失败(从头耐药),或者作为初始反应后的进展(获得性耐药)。4单一内分泌药物和与靶向药物组合的最佳顺序尚未确定,是研究重点。
更新日期:2019-06-04
down
wechat
bug